TABLE 1.
Current amniotic membrane products (Features and indications).
| Name of the product or the brand | Features | Approval | Indication | References |
|---|---|---|---|---|
| Amniofix® (MiMedx) | Dehydrated amniotic membrane + EGF, KGF, HA, IL-6 | FDA/AATB | -Chronic wounds | Fetterolf and Snyder, (2012); Mimedx, (2021) |
| -Debridement | ||||
| -Amputations | ||||
| -Dehiscence | ||||
| -Decubitus ulcers | ||||
| -Trauma | ||||
| -Pilonidal cysts | ||||
| -Burns | ||||
| EpiFix® (MiMedx) | Dehydrated amniotic membrane + EGF, KGF, HA, IL-6 | FDA/AATB | -Healing defects | Fetterolf and Snyder, (2012); Mimedx, (2021) |
| - Diabetic food ulcers | ||||
| -Varicose ulcers | ||||
| -Decubitus ulcers | ||||
| -Wounds | ||||
| -Desbridement | ||||
| SXBarrier® (SurgiLogix) | Cryopreserved amniotic membrane + PDFF-AA, PDGF-BB, bFGF, TGF-β1, EGF, FGF, VEGF | FDA | -Wounds | Surgilogix, (2020) |
| -Surgical Incision | ||||
| -Tissue regeneration | ||||
| Surgraft® (Surgenex) | Dehydrated amniotic membrane | FDA | -Diabetic food ulcers | Surgenex, (2021) |
| -Wounds | ||||
| -Food injuries | ||||
| -Orthopedical surgeries | ||||
| Biovance® (Alliqua Biomedical/Celularity) | Decellularized Dehydrated amniotic membrane | FDA | - Non-infected partial-thickness wounds | BioMedical, (2020) |
| -Chronic wounds | ||||
| -Diabetic food ulcers | ||||
| -Pressure ulcers | ||||
| -Venous ulcers | ||||
| -Surgical wounds | ||||
| -Burns | ||||
| -Trauma wounds | ||||
| Clarix®1K (Amiox/BioTissue) | Cryopreserved amniotic membrane from umbilical cord | FDA/AATB/ISO | -Complex Bone and Joint Reconstruction ---Soft Tissue Repair and Reconstruction | Morkin and Hamrah, (2018); Biotissue, (2022) |
| -Nerve Repair and Decompression | ||||
| -Joint Arthroplasty and Arthrodesis | ||||
| -Cartilage Repair | ||||
| -Fractures and Non-unions | ||||
| -Traumatic Wounds and Reconstruction, | ||||
| -Surgical Wound Healing | ||||
| -Dehiscence | ||||
| Clarix®100 (Amiox/BioTissue) | Thinner cryopreserved amniotic membrane | FDA/AATB/ISO | -Minimally Invasive Achilles | Morkin and Hamrah, (2018); Biotissue, (2022) |
| -Midfoot/Forefoot Fractures | ||||
| -Tendon/Nerve Repair | ||||
| -Ganglion Cyst Excision | ||||
| -Bunionectomy | ||||
| -Cheilectomy | ||||
| Neox®1K (Amiox/BioTissue) | Cryopreserved ultra-thick amniotic membrane | FDA/AATB/ISO | Diabetic Foot Ulcers | Morkin and Hamrah, (2018); Biotissue, (2022) |
| -Chronic Wounds | ||||
| -Venous Leg Ulcers | ||||
| -Arterial Ulcers | ||||
| -Pressure Ulcers | ||||
| -Wound Dehiscence | ||||
| -Burns | ||||
| Neox®100 (Amiox/BioTissue) | Cryopreserved amniotic membrane | FDA/AATB/ISO | Diabetic Foot Ulcers | Morkin and Hamrah, (2018); Biotissue, (2022) |
| -Chronic Wounds | ||||
| -Dehisced Wounds | ||||
| -Granulating/Epithelializing Wounds | ||||
| -Hypertrophic Scars/Keloids | ||||
| -Non/Minimally Exudating | ||||
| -Wounds | ||||
| -Pressure Ulcers | ||||
| -Venous Ulcers | ||||
| -Burns. | ||||
| -Neox®RT (Amiox/BioTissue) | Cryopreserved amniotic membrane | FDA/AATB/ISO | Diabetic Foot Ulcers | Morkin and Hamrah, (2018); Biotissue, (2022) |
| -Chronic Wounds | ||||
| -Venous Leg Ulcers | ||||
| -Arterial Ulcers | ||||
| -Pressure Ulcers | ||||
| -Wound Dehiscence | ||||
| -Burns | ||||
| -Prokera® (Amiox/BioTissue) | Cryopreserved amniotic membrane + cleared | FDA/AATB/ISO | -Keratitis | Morkin and Hamrah, (2018); Biotissue, (2022)) |
| -Corneal scars | ||||
| -Chemical burns | ||||
| -Corneal defects | ||||
| -Partial limbal stem cell deficiency | ||||
| -Inflammatory ocular surface diseases | ||||
| -Plurivest® -Demavest (Aedicell) | Cryopreserved amniotic membrane and γ ray irradiated + TGF 1, HGF, PDFG-BB, PIG-F, SDF-1, VEGF, TIMP 1, 2, IL-4,6,8,10 | FDA/AATB | -Partial and Full Thickness | AediCell, (2022) |
| -Wounds | ||||
| -Drainage Wounds | ||||
| -Trauma Wounds (abrasions, lacerations, and skin tears) | ||||
| -Second Degree Burns | ||||
| -Diabetic Ulcers | ||||
| -Pressure Ulcers | ||||
| -Venous Ulcers | ||||
| -Chronic Vascular Ulcers | ||||
| -Surgical (donor sites/grafts post-surgery, post-laser surgery, podiatric) | ||||
| AmnioClear (LiventaBioscience) | Amniotic membrane | FDA | -Wounds | Liventabioscience, (2014) |
| -Diabetic food ulcers | ||||
| -AmnioBioGraft® (Alamo Biologics) | Amniotic membrane single | FDA/AATB | -Regenerative medicine | Biologics, (2022) |
| -Wound management | ||||
| -Chronic and non-healing dermal wounds | ||||
| -Cutaneous wound care | ||||
| -Reconstructive medicine | ||||
| -Ocular injuries and reparative eye work | ||||
| -Burn Care | ||||
| -AmnioBioGraft +® (Alamo Biologics) | Amniotic membrane dual layer | FDA/AATB | -Regenerative medicine | Biologics, (2022) |
| -Wound management | ||||
| -Chronic and non-healing dermal wounds | ||||
| -Cutaneous wound care | ||||
| -Reconstructive medicine | ||||
| -Ocular injuries and reparative eye work | ||||
| -Burn Care | ||||
| -AmnioBioGraft Cord® (Alamo Biologics) | Amniotic membrane from Umbilical cord | FDA/AATB | -Regenerative medicine | Biologics, (2022) |
| -Wound management | ||||
| -Chronic and non-healing dermal wounds | ||||
| -Cutaneous wound care | ||||
| -Reconstructive medicine | ||||
| -Ocular injuries and reparative eye work | ||||
| -Burn Care | ||||
| -XWRAP® (Applied Biologics) | Amniotic membrane | FDA | - Minimize scarring at surgical injury sites | Biologics, (2016) |
| - Protection of nerves and tendons at injury sites | ||||
| -Allowrap® (Allosource) | The amniotic membrane of double layer | FDA | -Reduction of spinal adhesions | Sanders and Annest, (2018) |
| -Trauma | ||||
| -Sports medicine | ||||
| -Amnioshield® (αtec) | Dehydrated amniotic membrane | FDA | -Reduce scars | αtec, (2022) |
| -Chronic wounds | ||||
| -Healing promotion | ||||
| -PalinGen® (AmnioTechnolog) | Amniotic membrane + collagen + Growth factors + Extracellular matrix proteins | FDA/AATB | -Wounds | AmnioTechnology, (2017) |
| -Reduce scars | ||||
| -Diabetic food ulcers | ||||
| -AmnioExcel® | Amniotic membrane + Corion + Extracellular matrix proteins + Growth factors + Cytokines | FDA | -Wounds | Integra, (2022) |
| -AmnioExcel Plus® | ||||
| -Omnigraft® (Integra Bioscience) |
FDA, food and drug administration; AATB, american association of tissue bank; ISO, international organization for standardization; IL, Interleukin; VEGFA, Vascular endothelial growth factor A; HA, Hyaluronic acid; HGF, Hepatocyte growth factor; EGF, Epidermal growth factor; FGF, Fibroblast growth factors; PIG-1, Serine/threonine-protein phosphatase 1; PDGF, Platelet-derived growth factor; KGF, Keratinocyte growth factor; NGF, Nerve growth factor; TGF, Transforming growth factor; TIMP, T cell immunoglobulin mucin protein; SDF, Stromal cell-derived factor.